
The PreA4₆₉₅ precursor protein of Alzheimer's disease A4 amyloid is encoded by 16 exons

H.G.Lemaire, J.M.Salbaum¹, G.Multhaupt¹, J.Kang, R.M.Bayney², A.Unterbeck², K.Beyreuther¹ and B.Müller-Hill

Institute für Genetik der Universität zu Köln, Weyertal 121, D-5000 Köln 41, ¹Zentrum für Molekulare Biologie, Universität Heidelberg, Im Neuenheimer Feld 282, D-6900 Heidelberg, FRG and ²Molecular Therapeutics Inc., 400 Morgan Lane, West Haven, CT 06516, USA

Received November 17, 1988; Revised and Accepted December 22, 1988

Accession no. X13428

ABSTRACT

Alzheimer's disease (AD) is characterized by the cerebral deposition of fibrillar aggregates of the amyloid A4 protein. Complementary DNA's coding for the precursor of the amyloid A4 protein have been described. In order to identify the structure of the precursor gene relevant clones from several human genomic libraries were isolated. Sequence analysis of the various clones revealed 16 exons to encode the 695 residue precursor protein (PreA4₆₉₅) of Alzheimer's disease amyloid A4 protein. The DNA sequence coding for the amyloid A4 protein is interrupted by an intron. This finding supports the idea that amyloid A4 protein arises by incomplete proteolysis of a larger precursor, and not by aberrant splicing.

INTRODUCTION

Alzheimer's disease (1) is the most common cause of dementia, afflicting about two million people in the USA (2). It is characterized by the formation of intraneuronal neurofibrillary tangles (3,4,5), extracellular amyloid plaques (3,4,5) and cerebrovascular amyloid deposits (5,6) in the brain. The major constituent of these depositions is the amyloid A4 protein or β -protein (3,4,6).

Recently, we isolated and sequenced a full-length cDNA clone encoding the fetal brain precursor of the amyloid A4 protein and localized the gene (PAD gene (7)) on chromosome 21 (8). The structure of the deduced amino acid sequence suggests that the fetal brain PreA4₆₉₅ protein is a glycosylated cell-surface receptor consisting of an N-terminal signal sequence, three extracellular domains, a transmembrane region and a cytoplasmic domain. The membrane spanning domain corresponds to residues 625–648 of the PreA4₆₉₅ protein and overlaps with the amyloid A4 peptide sequence (597–639). Three other groups reported the finding of longer transcripts of the PAD gene which all contain an extra exon encoding a peptide that is very similar to the Kunitz family of protease inhibitors (9,10,11). Schubert et al. (12) showed residues 18–44 of the amyloid A4 precursor protein to be very similar to a heparan sulfate proteoglycan core protein found in the nerve cell line PC12. Here we report exon–intron boundaries of the PAD gene. Our work excludes the possibility that the amyloid A4 peptide could be the product of alternative splicing.

MATERIALS AND METHODS*Genomic libraries and screening conditions*

Four different libraries were used: a) a chromosome 21 library (*Hind*III fragments in *lambda* charon 21A, courtesy of Dr M. Van Dilla) which was constructed at the Lawrence Livermore National Laboratory, Livermore, CA, under the auspices of the National Laboratory Gene Library Project, sponsored by the US Department of Energy, b) a

Nucleic Acids Research

1 57
ATGCTGCCGGGTTGGCACTGCTCTGCTGGCCGCTGGAGCGCTGGAGGTTG
MetLeuProGlyLeuAlaLeuLeuLeuAlaAlaTrpThrAlaArgAlaLeuGlu
1 19
ggcgccgcctcggaggggggggggcgcacgggtggggacggatacccccaaac
cttaaccaagctttaaagcagagaagcgggggctccgcaatgggaccctctctc...
.....tggcacaatatttttcagctctggctcagcaggcggcctggcaggcat
catgctctggtgagtcaggggatttataaagaatcggtgagctccacagtgatta
tatttatataggaaacgttaattttgtgtcagaaccttcagcaggtaccacaaaa
tctcatatgggaacgtgtaattttctatgataaattctttcggatattggttaattc
ctctctggtttatataaagaagcattgacctataggtgctagaacaacctctgtgac
atcatacaacttaactaaaggagtggtgaagccggggctgattcctaattgagaatga
gcagaatagaactcttttgatgatttccctgttcttccccaagcctctgccttgga
58
gctatggatactataactaactgaagcttcttcttcagTACCACCTGATGGTAATGCT
ValProThrAspGlyAsnAla
20
GGCTCTGGCTGAAACCCAGATTGCCATGTTCTGGCGAGACTGACATGCACATGAAT
GlyLeuLeuAlaGluProGlnIleAlaMetPheCysGlyArgLeuAsnMetHisMetAsn
GTCAGAATGGGAAGTGGGATTTCAGATCCATCAGGACCAAAACCTGCATGTACCAAG
ValGlnAsnGlyLysTrpAspSerAspProSerGlyThrLysThrCysIleAspThrLys
225
GAAGGCATCTCCAGATTGGCAAGAAgaagctctgctcgggtggatgcaatcagctt
GluGlyIleLeuGlnTyrCysGlnGlu
75
ggatcacatgcaattgttttcaaaaaattaaactctgttattttgcatcagtattttaa
ccctacagtaaaaactctggcttcccaatgatccaccattaccataatatttatttggca
ttaccctatgatatacatataaattgttttaaaattatgatgctgattatgaccatcac
taaacagtagtttaagatgctcacgacactttttattctcactctgtccaccagggtg
gagtcagtgccgaagatattgcttactgtagccttgacactaggctcaagcaatctct
cccactcagctcccgaattctctgactataggcaatgcccaccaggctgactgattt
ttttatttttagtagagatgggctctctgtgtggccaggctgtgaaactcgt
226
ggctcaacgactcctc.....tgctctcccaagCTTACCCTGAACCTG
ValTyrProGluLeu
76
CAGATCACCAATGTGGTAGAAGCCAAACCAAGTGCACCTCGAAGCTGTGCAAGCGG
GlnIleThrAsnValValGluAlaAsnGlnProValThrIleGlnAsnTrpCysLysArg
355
GGCCGCAAGCAGTGCAGAACCCATCCCCACTTTGGATTCCCTACCGCTGCTAGgtgag
GlyArgLysGlnCysLysThrHisProHisPheValIleProTyrArgCysLeu
119
cgg.....cttgaagctctattctcttgatgctctctcgg
356
gtaagaacctgtgatacagtggaatgcagggaagtggtttctcttcttccagtTGGT
alGly
120
GAGTTTGTAGTGCACCTCTCGTCTCCGACAAGTGCAAACTTCTACACCAGGAGGG
GluPheValSerAspAlaLeuLeuValProAspLysCysLysPheLeuHisGlnGluArg
468
ATGGATTTGCGAAACTCATCTCTACTGGCACCCTCGCCAAAGAGgtaccagccat
MetAspValCysGlyThrHisLeuHisThrPheValAlaLysGlu
156
aaattctttctatttgcagaagtgaaattctctggggcagtgctt.....
.....ttgtgaaattggttccataatattgggctgcatgtgattatttatgtggag
ttttcttacaatgaaacactctctctaccactcactgtttctcttaccattgtgag
469
ATCGTCAGTGAGAAGAGTACCAACTGCTCATGACTACGGCATGTGCTCCCTCGCGAATT
ThrCysSerGluLysSerThrAsnLeuHisAspTyrGlyMetLeuLeuProCysGlyIle
157
GACAGTTCCGAGGGGTAGAGTTTGTGTGTTGCCACTGGCTGAAAGAAAGTACAATGTC
AspLysPheArgGlyValGluPheValCysCysProLeuAlaGluLeuSerAspAsnVal
GATCTGCTGATTCGGAAGAGGATGACTCGGATGTCGTGGGGCGGAGCAGCACAGAC
AspSerAlaAspAlaGluLeuAspSerAspValTrpTrpGlyGlyAlaAspThrAsp

662
TATGCAGATGGGAGtaaggggtggccttctgttcagcctcagagatgctgaaacatttg
TyrAlaAspGly21
221
863
TGAAGACAAA
rGluAspLys
222
tatggagatttggatcctgtaaatcaatc.....
GTACTGAACTAGCAGAGAGGAAAGAACTGGCTGAGGTGGAAAGAAAGACCGCATGAT
ValValGluValAlaGluGluGluValAlaGluValGluGluGluAlaAspAsp
GACGAGGACGATGAGGATGGTATGAGGTAGAGAAAGAGGCTGAGGAACCTACGAAGAA
AspGluAspAspGluAspGlyAspGluValGluGluGluAlaGluProTyrGluGlu
GCCACAGAGAACCCAGCAGTTCGCCACCACCACCACCACCACAGAGTCTGTGGAA
AlaThrGluArgThrThrSerIleAlaThrThrThrThrThrGluSerValGlu
865 *
GAGGTGGTTCGAG.....aaatcagcgttctctatttaa
GluValValArgV
289
cggatggattattctgttggctgtttttctcacaacctctctctctacttt
* 866
atagTCTTACAACAGCAGCCAGTACCCTGATGCCGTTGACAAGTATCTFCAGACACT
alProThrThrAlaAlaSerThrProAspAlaValAspLysTyrLeuGluThrPro
290
GGGATGAGAATGACATGCCATTTCCAGAAAGCCAAAGAGGCTTGGAGCCCAAGCAG
GlyAspGluAsnGluHisAlaHisPheGlnLysAlaLysLeuArgLeuGluAlaLysHis
999
CGAGAGAGATGCTCCAGTgaagctcggctcttccatcatt.....
ArgGluArgMetSerGln
333
.....aaagatcgaactgatgaactttaaattcaaatgtttccttaattta
1000
tagGTTCATGAGAGATGGGAAGGCGAGACGCTCAGCAAGAACTTGCCTAAAGCTGAT
ValMetArgGluTrpGluGluAlaGluArgGlnAlaLysAsnLeuProLysAlaAsp
334
1074
AAGAAAGCAATTCAGTgaagctcgaactcgaacttctccta.....aaa
LysLysAlaValIleGln
358
scgtagaattagtcactgttggaaactgatgactctttaggatacttttagcactag
aagaaatggaatgagtgctcttttttagaagactgaaatgtgctctcctcactta
1075
ttcagtcctccatggcatatgtctctatgtaggcaGATTTCCAGGAGAACTGGATCT
HisPheGlnGluLysValGluSer
359
TTGACACAGAAAGCAGCCAGCAGAGACAGCAGCTGGTGGAGACACACATCCGCGAGATG
LeuGluGlnGluAlaAlaAsnGluArgGlnGlnLeuValGluThrHisMetAlaArgVal
GAAACCATGCTCAATACCGCCGCGCTGGCCGTTGGAGAACTACTACCCGCTCGCAG
GluAlaMetLeuAsnAspArgArgLeuAlaLeuGluAsnTyrIleThrAlaLeuGln
1233
GCTGTCTCTCCGCTGGTgaggtctcgtcagcggaggtccactcaggtccacagcag
AlaValProProArg
411
scgtagaagtgaggcactgggaactggaagccatacaaaagaatgagggaagctcct
tgagcactgttattcagaggttcaacctctcattccattcttgaaggtcaaaaggtca
1234
cagggcagctactcccaaggtcattctcaccagcagg.....CTCTGTAC
ProArgHis
412
GTGTTCAATATGCTAAAGAAATATGTCGCCGAGACAGAAAGCAGACAGCAGCACCTTA
ValPheAsnMetLeuLysLysTyrValArgAlaGluGlnLysAspArgGlnHisThrLeu
1362
AAGCAITTCAGCATGTGCCATGGTGGATCCCAAGAAAGCCGCTCAGATCCCGTCCAG
LysHisPheGluHisValArgMetValAspProLysLysAlaAlaGlnIleArgSerGln
454
.....tgatgcagGTTATGACACACCTCCGTTGATTATGAGCGC
ValMetThrHisLeuArgValIleTyrGluArg
455

lambda clones from the human genomic libraries were digested with different restriction endonucleases and subcloned into pUC19. Exon-containing fragments were detected by dideoxy sequencing (16,17) using exon-specific primers.

Polymerase chain reaction (PCR)

Amplifications with *TaqI*-polymerase (18) were performed in 100 μ l reaction mixtures containing 1 μ g genomic DNA (human embryonic liver) in 50mM KCl, 10mM Tris-HCl, pH 8.5, 2.5mM MgCl₂, each primer at 200nM, each dNTP (dATP, dCTP, dGTP, dTTP) at 200 μ M, gelatine at 200 μ g/ml and 2.5 units of polymerase (Cetus, Perkin-Elmer). The samples were overlaid with several drops of mineral oil and subjected to 40 cycles of amplification as follows. The samples were heated from 70° to 95° over a 2-minute period (denaturation), cooled to 55° over 2 minutes (annealing), heated to 70° for 1 minute (extension reaction). Thermal cycling was performed in a programmable heatblock (Perkin-Elmer, Cetus Instruments). After the final extension step, the samples were precipitated with ethanol and resuspended in 100 μ l TE buffer (19). 80 μ l of each sample was resolved on a 1.2% seaplaque-agarose gel and the fragment of interest was isolated as described (19). The amounts of synthesized fragments were approximately 200–500ng in each case. 50ng of each sample was used for cloning into the plasmid vector pUC19. The cloning of the exon-representing products was confirmed by sequence analysis.

DNA-sequencing

The sequences presented in figure 1 were derived by the chain termination method (16) using Klenow polymerase on single-stranded denatured plasmid DNA templates (17). Exon-specific synthetic primer-oligomers were synthesized on a Model 380 A DNA synthesizer (Applied Biosystems).

RESULTS AND DISCUSSION

Exon-specific clones isolated from the genomic libraries

The following fragments were isolated from the chromosome 21 libraries and cloned completely into the plasmid vector pUC19 (15): H1.30(2.8kb,exon1), E6.BA(1.8kb,exon2), H3.31(4.5kb,exon3), H2.31(7.5kb,exons4,5), 4A(7.0kb,exon7), H1.41(3.8kb,exons 8,9), APC1(1.2kb, exon 14), E4.5(2.8kb, exon 15), H1.23(7.0kb, exon 16). The lengths of the different fragments and the numbers of the corresponding exons are shown in brackets. Clone P1.21(1.2kb,exon12) was isolated from the human genomic library from B.Horsthemke and represents only a part of a larger insert from the corresponding *lambda* clone. Clone HG440(appr.15kb) was isolated from the human leukocyte genomic library (Genofit) and a 4.5kb fragment containing exon 11 was subcloned in pUC19.

Exon-specific clones synthesized by PCR (18)

Lambda clones specific for the exons 6,10 and 13 could not be detected in the genomic libraries mentioned above. Three *lambda* clones specific for exon 6 were isolated from the human leukocyte genomic library (Genofit) but up to now they have not been subcloned into pUC19. In order to find out whether the putative exons 6,10 and 13 were interrupted by further introns we probed the DNA by the PCR amplification method (18) as follows. The exon–intron boundaries of exons 5 and 7,9 and 11, 12 and 14, respectively had been determined by the analysis of neighbouring genomic clones. So we used two synthetic oligonucleotides with their 5' ends corresponding to the first or last position of the putative exon. The products of amplification procedures were shown to have the same size as the corresponding cDNA fragments on a 2% agarose gel (data not shown), and sequence analysis of the cloned fragments revealed no further introns.

Exon-intron boundaries determined by DNA sequence analysis

Partial sequence analysis of the various genomic clones revealed that the PreA4₆₉₅ transcript is a splicing product containing 16 exons (figure 1). In each case the exon-intron boundary as well as the whole exon was sequenced. As expected (20), each intron starts with a 'GT' and ends with a 'AG'.

Only two of the genomic clones isolated from the genomic libraries contain two exons (clones H2.31, 7.5Kb, exons 4 and 5, and H1.41, 3,8kb, exons 8 and 9). All the other clones contain one exon each, even HG440 (appr. 15 Kb) and P1.21 (appr. 14 Kb). Hybridization experiments (data not shown) showed that the neighbouring genomic clones did not overlap, thus the size of the gene cannot yet be determined. From the known insert sizes a minimal length of 50 Kb can be calculated.

Recently, three groups reported the cloning of preA4-cDNAs containing an extra exon encoding a protease-inhibitor like sequence (9,10,11). Kitaguchi et al. (10) isolated a cDNA containing the exon coding for the protease-inhibitor like sequence together with a 3'-adjacent small exon coding for a peptide similar in sequence to the MRC OX2 antigen (21). They proposed (10) that the three different preA4-mRNA's are due to alternative splicing of a single PAD gene. For this form the PAD gene provides 18 exons. The use of the PreA4₆₉₅ cDNA in the identification of the genomic structure of the PAD gene would have failed to reveal the trypsin inhibitor coding exon or any further exons. In figure 1 the positions of the exon-intron boundaries where the trypsin-inhibitor-like exon and the other additional exon (10) have been found are marked by asterisk's (bases 865, 866).

Exon-intron boundaries and the structure of the PreA4₆₉₅ protein.

Comparison of the exon-intron-structure of the PAD-gene to the deduced protein sequence shows that exon 1 contains the coding region for the signal peptide (22). Mita et al. (23) recently reported a cDNA coding for a further 73 amino acids at the N-terminus of the precursor. The significance of this finding is still unclear. Exons 2,3,4 and 5 span the cysteine-rich region, and exons 5 and 6 provide the highly negatively charged domain (8). The amino acid sequence encoded by exon 6 shows some similarity (31 %) to human prothymosin alpha-1 (24) but this similarity is mainly based on the acidic amino acids in these two peptides. The protein sequence encoded by exons 7 to 13 contains the two putative N-glycosylation sites (8,25) of the PreA4₆₉₅-protein. The amyloid A4 protein extends across the border between exons 14 and 15, a fact that supports the idea that accumulation of this peptide in the brain tissue is due to degradation of the precursor and not to aberrant splicing. Finally the putative transmembrane region is completely contained in exon 15 and most of the putative cytoplasmic domain is coded for by exon 16.

ACKNOWLEDGEMENTS

We thank A.Starzinski-Powitz for the human embryonic DNA, B.Horsthemke for the human genomic library, J.Hesselbach and A.Lee for excellent technical assistance, and B.Kisters for help with the computers. This work was supported by a grant of the Fritz Thyssen Stiftung to B.M.H. and grants of the Deutsche Forschungsgemeinschaft through SFB 317, the Bundesministerium für Forschung und Technologie and the Fonds der chemischen Industrie to K.B.

REFERENCES

1. Alzheimer, A. (1907), *Allg.Z.Psychiat.* **64**, 146-148
2. Katzman, R. (1986), *N. Engl. J. Med.* **314**, 964-973.

3. Masters, C.L., Simms, G., Weinmann, N.A., Multhaup, G., McDonald, B.L. and Beyreuther, K. (1985), *Proc. Natl. Acad. Sci. USA* **82**, 4245–4249
4. Masters, C.L., Multhaup, G., Simms, G., Pottgiesser, J., Martins, R.N. and Beyreuther, K. (1985), *EMBO J.* **4**, 2757–2763
5. Katzman, R. (ed.) (1983), *Biological Aspects of Alzheimer's Disease (Banbury Report 15)*, Cold Spring Harbor Laboratory, New York
6. Glenner, G.G. and Wong, C.W. (1984), *Biochem. Biophys. Res. Commun.* **120**, 1131–1135
7. Salbaum, J.M., Weidemann, A., Lemaire, H.G., Masters, C.L. and Beyreuther, K. (1988), *EMBO J.* **7**, 2807–2813
8. Kang, J., Lemaire, H.G., Unterbeck, A., Salbaum, J.M., Masters, C.L., Grzeschik, K.H., Multhaup, G., Beyreuther, K. and Müller-Hill, B. (1987), *Nature* **325**, 733–736
9. Tanzi, R.E., McClatchey, A.I., Lamperti, E.D., Villa-Komaroff, L., Gusella, J.F. and Neve, R.L. (1988), *Nature* **331**, 528–530
10. Kitaguchi, N., Takahashi, Y., Tokushima, Y., Shiojiri, S., and Ito, H. (1988), *Nature* **331**, 530–532
11. Ponte, P., Gonzalez-DeWhitt, P., Schilling, J., Miller, J., Hsu, D., Greenberg, B., Davis, K., Wallace, W., Lieberburg, I., Fuller, F. and Cordell, B. (1988), *Nature* **331**, 525–527
12. Schubert, D., Schroeder, R., LaCorbiere, M., Saitoh, T., and Cole, G. (1988), *Science* **241**, 223–226.
13. Feinberg, A.P. and Vogelstein, B. (1984), *Anal. Biochem.* **137**, 266
14. Lambda SorbTM Phage Adsorbent Kit, Promega Biotec, Madison, WI 53711, USA.
15. Yanisch-Perron, C., Vieira, J. and Messing, J. (1985), *Gene* **33**, 103–119
16. Sanger, F., Nicklen, S. and Coulson, A.R. (1977), *Proc. Natl. Acad. Sci. USA* **74**, 5463–5467
17. Chen, E.J. and Seeburg, P.H. (1985), *DNA* **4**, 165–170
18. Saiki, R.K., Gelfand, D.H., Stoffel, S., Scharf, S.J., Higuchi, R., Horn, G.T., Mullis, K.B. and Erlich, H.A. (1988), *Science* **239**, 487–491
19. Maniatis, T., Fritsch, E.F., Sambrook, J., *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY) (1982).
20. Leder, A., Miller, H.J., Hamer, D.H., Seidman, J.G., Norman, B., Sullivan, M. and Leder, P. (1978), *Proc. Natl. Acad. Sci. USA* **75**, 6187–6191
21. Clark, M.J., Gagnon, J., Williams, A.F. and Barclay, A.N. (1985), *EMBO J.* **4**, 113–118
22. Blobel, G. and Dobberstein, B. (1975), *J. Cell. Biol.* **67**, 852–862
23. Mita, S., Sadlock, J., Herbert, J., and Schon, E.A. (1988), *Nucleic Acids Res.* **16**, 9351.
24. Goodall, G.J., Dominguez, F. and Horecker, B.L. (1986), *Proc. Natl. Acad. Sci. USA* **83**, 8926–8928
25. Dyrks, T., Weidemann, A., Multhaup, G., Salbaum, J.M., Lemaire, H.G., Kang, J., Müller-Hill, B., Masters, C.L. and Beyreuther, K. (1988), *EMBO J.* **7**, 949–957